MedTrace Logo

Alpha Radiation Emitters Device for the Treatment of of Malignant Cutaneous Tumors

NCT04068155 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2024-11-22

No results posted yet for this study

Summary

A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for Malignant Cutaneous Tumors

Conditions

Interventions

DEVICE

DaRT- Diffusing Alpha-emitters Radiation Therapy

Seed(s) loaded with Radium-224 for local intratumoral irradiation with the destructive power of alpha particles

Sponsors & Collaborators

  • Alpha Tau Medical LTD.

    lead INDUSTRY

Principal Investigators

  • Dr Pascal POMMIER · Centre Leon Berard

  • Pr Jean Michel HANNOUN LEVI · Antoine Lacassagne Cancer Center

  • Dr Camille VERRY · University Hospital, Grenoble

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-01
Primary Completion
2025-01-31
Completion
2025-01-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04068155 on ClinicalTrials.gov